Eli Lilly makes Zepbound vials cheaper for self-paying patients
Eli Lilly has announced significant price reductions and expanded options for its weight-loss drug Zepbound (tirzepatide) for self-paying patients. Here are the key details:
New Pricing and Availability
- Launched new 7.5 mg and 10 mg Zepbound single-dose vials, available for $499 per month through the Zepbound Self Pay Journey Program12
- Reduced prices for existing doses:
- 2.5 mg dose lowered to $349 per month (from $399 previously)
- 5 mg dose lowered to $499 per month (from $549 previously)13
Zepbound Self Pay Journey Program
- New program offering discounted pricing on 7.5 mg and 10 mg vials
- Applies to first fill and refills within 45 days of previous delivery
- 7.5 mg and 10 mg vials priced at $599 and $699 respectively if refilled outside the 45-day window1
Distribution and Eligibility
- New pricing available exclusively through LillyDirect Self Pay Pharmacy Solutions
- Removes third-party supply chain entities to provide direct savings to patients outside of insurance1
- Patients must have a valid, on-label prescription from a healthcare provider4
Impact and Rationale
- Aims to improve affordability and access for self-paying patients with obesity
- Responds to lack of systematic insurance coverage for obesity treatment
- Lilly committed to working towards comprehensive care and coverage for obesity1
These price reductions and expanded options represent Lilly's efforts to compete in the growing weight-loss drug market while addressing affordability concerns for patients paying out-of-pocket.
Sources:
1. https://www.prnewswire.com/news-releases/lilly-launches-additional-zepbound-vial-doses-and-offers-new-savings-for-self-pay-patients-302383878.html
2. https://www.foxbusiness.com/lifestyle/eli-lilly-cuts-prices-zepbound-weight-loss-drug-again
3. https://www.managedhealthcareexecutive.com/view/lilly-lowers-prices-of-some-zepbound-doses-for-self-pay-patients
4. https://www.healthline.com/health-news/eli-lilly-cuts-zepbound-prices